AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). Meeting Abstract

International Collaboration

cited authors

  • Socinski, Mark A.; Spira, Alexander I.; Paz-Ares, Luis G.; Reck, Martin; Lu, Shun; Nishio, Makoto; Li, Jiang; Zhou, Yunfei; Rhee, Joon Whan; Duque, Sandra Chica; Yu, Xinmin

Publication Date

  • May 20, 2021

webpage

published in

category

volume

  • 39

issue

  • 15